Ilaria Pace

Bologna, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Cancer of unknown primary genomic profiling from cell-free DNA provides insights into CUP biology and vulnerabilities.

Cancer of unknown primary genomic profiling from cell-free DNA provides insights into CUP biology and vulnerabilities.

Journal: Frontiers in medicine

Published: December 29, 2025

Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC.

Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 13, 2025

Profibrotic Molecules Are Reduced in CRISPR-Edited Emery-Dreifuss Muscular Dystrophy Fibroblasts.

Profibrotic Molecules Are Reduced in CRISPR-Edited Emery-Dreifuss Muscular Dystrophy Fibroblasts.

Journal: Cells

Published: July 18, 2025

Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort Study.

Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort Study.

Journal: Dermatology and therapy

Published: October 10, 2024

Synergic action of MicroRNAs and Wnts delivered by motor neuron EVs in promoting AChR clustering.

Synergic action of MicroRNAs and Wnts delivered by motor neuron EVs in promoting AChR clustering.

Journal: Cell communication and signaling : CCS

Published: August 08, 2024

Gastroesophageal circulating tumor cell crosstalk with peripheral immune system guides CTC survival and proliferation.

Gastroesophageal circulating tumor cell crosstalk with peripheral immune system guides CTC survival and proliferation.

Journal: Cell death & disease

Published: August 05, 2024

Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary.

Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: November 05, 2023

ARID1A in cancer: Friend or foe?

ARID1A in cancer: Friend or foe?

Journal: Frontiers in oncology

Published: January 02, 2023

Showing 1-8 of 8

Last Updated: 09/26/2026